Antimicrobial activity and spectrum of sparfloxacin tested against erythromycin-resistant Streptococcus pneumoniae isolates

Diagnostic Microbiology and Infectious Disease

Volumn 24, Issue 2, 1996, Pages 113-116

  Barrett, Mary S ^a   Jones, Ronald N ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFOTAXIME; CIPROFLOXACIN; CLARITHROMYCIN; ERYTHROMYCIN; OFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL PNEUMONIA; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG EFFICACY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

EID: 0029968892     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/0732-8893(96)00014-4     Document Type: Article

References (13)

1. Appelbaum PC (1992) Antimicrobial resistance to Streptococcus pneumoniae: An overview. Clin Infect Dis 15:77-83.
2. Breiman RF, Butler JC, Tenover FC, Elliot JA, Facklam RR (1994) Emergence of drug-resistant pneumococcal infections in the United States. JAMA 271:1831-1835.
3. Goldstein FW, Pean Y, Gertner J, Guerrier ML, and the French Study Group (1995) Antimicrobial susceptibility of 1317 S. pneumoniae, H. influenzae, and B. catarrhalis isolated from community-acquired respiratory tract infections during a multicenter study. Abstract 1463. In: 35th Intersci Congress Antimicrob Agents Chemother Conf, San Francisco, CA.
4. Gootz TD, Brighty KE, Anderson MR, Schmieder BJ, Haskell SL, Sutcliffe JA, Castaldi MJ, McGuirk RP (1994) In vitro activity of CP-99,219, a novel 7-(3-azabiocyclo[3.1.0]hexyl) naphthyridone antimicrobial. Diagn Microbiol Infect Dis 19:235-243.
5. Jenssen WD, Thakker-Varia S, Dubin DT, Weinstein MP (1987) Prevalence of macrolides-lincosamides-streptogramin B resistance and erm gene classes among clinical strains of staphylococci and streptococci. Antimicrob Agents Chemother 31:883-888.
6. Johnson JH, Cooper MA, Andrews JM, Wise R (1992) Pharmacokinetics and inflammatory fluid penetration of sparfloxacin. Antimicrob Agents Chemother 36:2444-2445.
7. Jones RN, Kehrberg EN, Erwin ME, Anderson SC, and the Fluoroquinolone Resistance Surveillance Group (1994) Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States. I. Study on the threat of emerging resistances: Real or perceived? Diagn Microbiol Infect Dis 19:203-215.
8. Jorgensen JH, Ferrato MJ, McElmeel ML, Spargo J, Swenson JM, Tenover FC (1994) Detection of penicillin and extended-spectrum cephalosporin resistance among Streptococcus pneumoniae clinical isolates by use of the Etest. J Clin Microbiol 32:159-163.
9. Kojima T, Inoue M, Mitsuhashi S (1989) In vitro activity of AT-4140 against chemical bacterial isolates. Antimicrob Agents Chemother 33:1980-1988.
10. Moreno S, Garcia-Leoni ME, Cercenado EM, Diaz MD, Bernaldo de Quiros JCL, Bouza E (1995) Infections caused by erythromycin-resistant Streptococcus pneumoniae: Incidence, risk factors, and response to therapy in a prospective study. Clin Infect Dis 20:1195-1200.
11. National Committee for Clinical Laboratory Standards (1995) Performance standards for antimicrobial susceptibility testing. Sixth informational supplement, M100-S6. National Committee for Clinical Laboratory Standards, Villanova, PA.
12. Sutton LD, Jones RN (1995) Suggested modifications for disk diffusion susceptibility testing criteria for levofloxacin and sparfloxacin following tests with a predictor panel of ciprofloxacin-resistant clinical isolates. J Clin Microbiol 33:146-148.
13. Wolfson JS, Hooper DC (1992) The fluoroquinolones: Clinical and laboratory considerations. Clin Microbiol Newslett 14:1-7.